Lakefront Biotherapeutics (GLPGF) EBITDA Margin Growth (5y) (2019 - 2026)
Powered by 
Analysis
Lakefront Biotherapeutics (GLPGF) EBITDA Margin Growth (5y) (2019 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 210.98 Bn | 196.99 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 181.24 Bn | 178.06 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.38 Bn | 124.53 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.97 Bn | 74.97 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.59 Bn | 56.41 Bn | 1.37 Bn |
| 6 | Moderna | 54.80 Bn | 49.67 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.09 Bn | 30.78 Bn | 992.69 Mn |
| 8 | Biogen | 31.34 Bn | 30.05 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 30.11 Bn | 30.11 Bn | 1.16 Mn |
| 10 | Lakefront Biotherapeutics | 1.73 Bn | 1.73 Bn | 3.51 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -32,547.00 |
| Mar 31, 2026 | -93,832.00 |
| Dec 31, 2025 | 11,774.00 |
| Sep 30, 2025 | -29,441.00 |
| Jun 30, 2025 | 129.00 |
| Mar 31, 2025 | -16,708.00 |
| Dec 31, 2024 | 19,287.00 |
| Sep 30, 2024 | -17,130.00 |
| Jun 30, 2024 | -32,812.00 |
| Mar 31, 2024 | 10,804.00 |
| Dec 31, 2023 | 3,327.00 |
| Sep 30, 2023 | -3,617.00 |
| Jun 30, 2023 | 4,545.00 |
| Mar 31, 2023 | 6,027.00 |
| Dec 31, 2022 | 6,712.00 |
| Sep 30, 2022 | 8,246.00 |
| Jun 30, 2022 | 2,501.00 |
| Mar 31, 2022 | 1,751.00 |
| Dec 31, 2021 | -24,347.00 |
| Jun 30, 2021 | -920.00 |